Jupiter Asset Management Ltd. Boosts Stock Position in Illumina, Inc. $ILMN

Key Points

• Jupiter Asset Management increased its Illumina stake by 54.4% in the fourth quarter, ending with 271,354 shares worth about $35.6 million.
• Illumina’s stock has attracted heavy institutional ownership overall, with hedge funds and other institutional investors holding 89.42% of the shares. Several firms also added to their positions during recent quarters.
• The company reported better-than-expected quarterly results, including $1.15 EPS on $1.09 billion in revenue, and it recently launched new oncology research tools that could support future growth.

Jupiter Asset Management Ltd. boosted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 54.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 271,354 shares of the life sciences company's stock after purchasing an additional 95,594 shares during the quarter. Jupiter Asset Management Ltd. owned about 0.18% of Illumina worth $35,591,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ILMN. Capital World Investors raised its position in shares of Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company's stock valued at $1,897,178,000 after buying an additional 3,331,542 shares during the last quarter. Nordea Investment Management AB boosted its position in Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company's stock worth $124,145,000 after acquiring an additional 911,843 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Illumina in the 4th quarter worth approximately $73,532,000. State Street Corp raised its holdings in Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company's stock valued at $569,800,000 after acquiring an additional 382,520 shares during the last quarter. Finally, Duquesne Family Office LLC acquired a new position in Illumina in the 2nd quarter valued at $28,682,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Keith A. Meister sold 225,067 shares of Illumina stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. The trade was a 5.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the company's stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares of the company's stock, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 330,160 shares of company stock worth $48,028,308. 2.90% of the stock is currently owned by corporate insiders.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina and SPT Labtech launched fireflyGO, a new automation platform designed to make targeted oncology research faster, simpler, and more scalable. The product is integrated with Illumina’s MiSeq i100 Series and could help broaden adoption of its sequencing workflow. Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
• Positive Sentiment: Illumina also introduced a distributed whole-genome sequencing solution for MRD research, expanding its oncology portfolio and making it easier for more labs to adopt molecular residual disease testing in clinical research. That supports the company’s long-term growth narrative in precision oncology. Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
• Neutral Sentiment: A separate marketwide report noted that the broader stock market reached fresh highs on upbeat macro news. While this may be helping overall sentiment, it is not specific to Illumina’s business. Dow Jones Futures: Stock Market Hits Highs On U.S.-Iran Deal; Dell Surges On Earnings
• Neutral Sentiment: One article flagged Illumina as a strong momentum stock, which may reinforce positive trader sentiment, but it did not include new fundamental information. Here's Why Illumina (ILMN) is a Strong Momentum Stock

Illumina Price Performance

ILMN stock opened at $158.70 on Friday. The company has a market cap of $24.01 billion, a PE ratio of 28.85, a price-to-earnings-growth ratio of 2.49 and a beta of 1.42. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average price of $132.92 and a two-hundred day moving average price of $131.80. Illumina, Inc. has a 12-month low of $78.79 and a 12-month high of $158.79.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the business posted $0.97 EPS. The company's quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts predict that Illumina, Inc. will post 5.2 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Evercore reaffirmed an "outperform" rating on shares of Illumina in a research report on Friday, May 1st. Royal Bank Of Canada started coverage on Illumina in a research note on Thursday, May 14th. They issued an "outperform" rating and a $170.00 price target on the stock. Barclays lifted their price target on Illumina from $110.00 to $122.00 and gave the company an "underweight" rating in a report on Friday, May 1st. Canaccord Genuity Group cut their price objective on shares of Illumina from $150.00 to $140.00 and set a "hold" rating on the stock in a report on Friday, May 1st. Finally, Robert W. Baird set a $137.00 target price on shares of Illumina in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of "Hold" and an average price target of $137.75.

Illumina Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.